HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Friday, 8 August 2014

Recently published CEAs

Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers.  From the ones listed this time, here's a few in our areas of research interest:

Dakin HA, Wordsworth S, Rogers CA, et al; on behalf of the IVAN Study Investigators. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open.x2014 Jul 29;4(7):e005094. PubMed PMID: 25079928.

Burger EA, Sy S, Nygård M, et al. Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent HPV vaccine in Norway. J Infect Dis. 2014 Jul 23. [Epub ahead of print] PubMed PMID: 25057044.

Zueger PM, Schultz NM, Lee TA. Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review. Pharmacoeconomics. 2014 Jul 23. [Epub ahead of print] PubMed PMID: 25052903.

Jódar-Sánchez F, Ortega F, Parra C, et al. Cost-utility analysis of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. J Telemed Telecare. 2014 Jul 22. [Epub ahead of print] PubMed PMID: 25052387.